GLUCOTRACK INC
GCTKNASDAQTrading Snapshot
- Day Range
- $1.78 – $1.83
- 52-Week Range
- $1.77 – $136.29
- Volume
- $3.19B
- Avg Volume
- $2.28B
- Shares Outstanding
- 7.7M
- Next Earnings
- Nov 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $75,000
- Last Q Revenue
- $19,581
- P/E Ratio
- —
- P/S Ratio
- 19.2x
- EPS (TTM)
- $-115.36
- Dividend Yield
- —
- Dilution (1yr)
- +172.4%
Why Investors Own GCTK
- ✓High-growth profile — revenue up +0.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GLUCOTRACK INC
GCTK
StockOtter · stockotter.spaceAbout GLUCOTRACK INC
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
Glucotrack, Inc. (NASDAQ: GCTK) (âGlucotrackâ or the âCompanyâ) today announced the pricing of a âbest effortsâ public offering of 169,388 shares of
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
Shares of GlucoTrack Inc (NASDAQ:GCTK) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership.
Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi CEO Erik Emerson outlines LT-100 progress, ai² platform growth, and a strategy to discover, advance, and monetize assets.
Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent
LÅkahi Therapeuticsâ¢, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that The University of Alabama's Culverhouse College of Business will
Glucotrack Announces $11.5 Million Financing
Glucotrack, Inc. (NASDAQ: GCTK) (âGlucotrackâ or the âCompanyâ) today announced definitive agreements for convertible notes with an aggregate principal
Glucotrack, Inc. Announces Reverse Stock Split
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack (Nasdaq: GCTK) announced a 1-for-15 reverse stock split effective August 31, 2026, to support Nasdaq listing compliance.